Market overview
The global radiotherapy market is worth USD 7.2 bn in 2026 and is forecast to reach USD 14.0 bn by 2036, growing at a 6.8% CAGR. United States is the largest country market and Linear accelerators is the largest by product segment.
| Scope | Radiation therapy systems and associated software: linear accelerators, proton and ion systems, brachytherapy, radiosurgery and treatment planning for cancer care. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 6.8 bn |
| Value 2026 | USD 7.2 bn |
| Value 2036 | USD 14.0 bn |
| CAGR 2026-2036 | 6.8% |
| Volume 2026 | 3,043 units |
| Volume 2036 | 5,062 units |
| Average price 2026 | USD 2,380,000 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Radiotherapy market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 7.2 bn |
| 2027 | USD 7.7 bn |
| 2028 | USD 8.3 bn |
| 2029 | USD 8.8 bn |
| 2030 | USD 9.4 bn |
| 2031 | USD 10.1 bn |
| 2032 | USD 10.7 bn |
| 2033 | USD 11.5 bn |
| 2034 | USD 12.3 bn |
| 2035 | USD 13.1 bn |
| 2036 | USD 14.0 bn |
Radiotherapy market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Linear accelerators | 58.0% | 50.7% | USD 4.2 bn | 5.4% |
| Proton and heavy ion systems | 12.0% | 15.9% | USD 869 mn | 9.9% |
| Brachytherapy | 8.0% | 6.7% | USD 579 mn | 4.9% |
| Treatment planning and oncology software | 22.0% | 26.7% | USD 1.6 bn | 8.9% |
By application
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Prostate | 24.0% | 23.8% | USD 1.7 bn | 6.7% |
| Breast | 24.0% | 22.7% | USD 1.7 bn | 6.2% |
| Lung | 16.0% | 16.6% | USD 1.2 bn | 7.2% |
| Head and neck | 12.0% | 11.9% | USD 869 mn | 6.7% |
| Other cancers | 24.0% | 24.9% | USD 1.7 bn | 7.2% |
By technique
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| External beam | 80.0% | 78.0% | USD 5.8 bn | 6.5% |
| Brachytherapy | 8.0% | 7.0% | USD 579 mn | 5.4% |
| Systemic radioisotope | 12.0% | 15.0% | USD 869 mn | 9.2% |
By cancer site
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Breast | 22.0% | 21.0% | USD 1.6 bn | 6.3% |
| Prostate | 20.0% | 19.0% | USD 1.4 bn | 6.2% |
| Lung | 18.0% | 18.0% | USD 1.3 bn | 6.8% |
| Head and neck | 12.0% | 12.0% | USD 869 mn | 6.8% |
| Digestive and other | 28.0% | 30.0% | USD 2.0 bn | 7.5% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 62.0% | 58.0% | USD 4.5 bn | 6.1% |
| Cancer centres | 26.0% | 27.0% | USD 1.9 bn | 7.2% |
| Ambulatory radiotherapy centres | 12.0% | 15.0% | USD 869 mn | 9.2% |
Top 25 countries for radiotherapy by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 84.5% of 2026 revenue and the 25 countries below together hold 95.7%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 2.5 bn | 34.0% | USD 4.2 bn | 5.4% |
| 2 | China | USD 1.2 bn | 16.0% | USD 3.1 bn | 10.4% |
| 3 | Japan | USD 579 mn | 8.0% | USD 937 mn | 4.9% |
| 4 | Germany | USD 435 mn | 6.0% | USD 699 mn | 4.9% |
| 5 | France | USD 290 mn | 4.0% | USD 489 mn | 5.4% |
| 6 | India | USD 290 mn | 4.0% | USD 811 mn | 10.8% |
| 7 | United Kingdom | USD 290 mn | 4.0% | USD 517 mn | 6.0% |
| 8 | Italy | USD 217 mn | 3.0% | USD 364 mn | 5.3% |
| 9 | South Korea | USD 217 mn | 3.0% | USD 419 mn | 6.8% |
| 10 | Brazil | USD 181 mn | 2.5% | USD 364 mn | 7.2% |
| 11 | Spain | USD 175 mn | 2.4% | USD 312 mn | 5.9% |
| 12 | Canada | USD 108 mn | 1.5% | USD 185 mn | 5.5% |
| 13 | Netherlands | USD 80 mn | 1.1% | USD 137 mn | 5.6% |
| 14 | Australia | USD 64 mn | 0.9% | USD 110 mn | 5.7% |
| 15 | Mexico | USD 54 mn | 0.8% | USD 133 mn | 9.3% |
| 16 | Turkey | USD 47 mn | 0.7% | USD 115 mn | 9.3% |
| 17 | Russia | USD 42 mn | 0.6% | USD 73 mn | 5.6% |
| 18 | Poland | USD 38 mn | 0.5% | USD 92 mn | 9.2% |
| 19 | Saudi Arabia | USD 35 mn | 0.5% | USD 85 mn | 9.4% |
| 20 | Switzerland | USD 32 mn | 0.4% | USD 56 mn | 5.8% |
| 21 | Belgium | USD 30 mn | 0.4% | USD 52 mn | 5.7% |
| 22 | Indonesia | USD 28 mn | 0.4% | USD 69 mn | 9.3% |
| 23 | Egypt | USD 26 mn | 0.4% | USD 64 mn | 9.4% |
| 24 | Thailand | USD 25 mn | 0.3% | USD 62 mn | 9.3% |
| 25 | Taiwan | USD 24 mn | 0.3% | USD 41 mn | 5.4% |
| Rest of world | USD 314 mn | 4.3% | USD 541 mn | 5.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Varian
- Elekta
- Accuray
- IBA
Group 2: Regional and specialist players
- Hitachi
- Mevion Medical Systems
- Sumitomo Heavy Industries
- United Imaging
- Shinva Medical
- Eckert and Ziegler
- RaySearch Laboratories
- Sun Nuclear
- Theragenics
Group 3: Emerging and niche players
- Brainlab
- Best Medical International
- RefleXion Medical
- Xstrahl
- Sensus Healthcare
- ZAP Surgical Systems
- Radformation
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the radiotherapy market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 6.8% is calculated from the resulting values.
The market is divided by product, by application, by technique, by cancer site, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the radiotherapy market?
The global radiotherapy market is estimated at USD 6.8 bn in 2025 and USD 7.2 bn in 2026.
How fast will the radiotherapy market grow?
It is forecast to reach USD 14.0 bn by 2036, a compound annual growth rate of 6.8% from 2026, an increase of USD 6.7 bn.
Which country is the largest market for radiotherapy?
United States is the largest market by revenue at USD 2.5 bn in 2026, 34.0% of the global total. The three largest countries together hold 58.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 10.8% a year from 2026 to 2036.
Which radiotherapy segment is largest?
In the by product split, Linear accelerators is the largest segment with 58.0% of 2026 revenue.
Who are the leading radiotherapy companies?
Global leaders include Varian, Elekta, Accuray, IBA.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Cell Culture MediaUSD 7.4 bn · 8.0% CAGR
- Laboratory AutomationUSD 7.0 bn · 8.0% CAGR
- Infusion PumpUSD 6.9 bn · 5.2% CAGR
- Companion DiagnosticsUSD 7.6 bn · 11.5% CAGR
- Transdermal Drug DeliveryUSD 7.6 bn · 6.0% CAGR
- Cleanroom ConsumableUSD 6.7 bn · 7.5% CAGR
- Pen InjectorUSD 6.7 bn · 10.0% CAGR
- Mass SpectrometryUSD 6.6 bn · 7.0% CAGR